Kiran K Nagothu
Overview
Explore the profile of Kiran K Nagothu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, Nagothu K, Desai V, Lee T, Branham W, Moland C, et al.
Kidney Int
. 2009 Aug;
76(10):1049-62.
PMID: 19710628
Our previous studies suggest that peroxisome proliferator-activated receptor-alpha (PPARalpha) plays a critical role in regulating fatty acid beta-oxidation in kidney tissue and this directly correlated with preservation of kidney morphology...
2.
Wangila G, Nagothu K, Steward 3rd R, Bhatt R, Iyere P, Willingham W, et al.
Toxicol In Vitro
. 2006 Jul;
20(8):1300-12.
PMID: 16814979
Copper(2)(II)(3,5-ditertiarybutylsalicylate)(4)(ethanol)(4), Cu(2)(II)(3,5-DTBS)(4)(Eth)(4), was synthesized and characterized for evaluation as an anti-apoptotic superoxide dismutase (SOD)-mimetic in an in vitro 50 microM cis-diamminedichloroplatinum(II), [Pt(II)(NH(3))(2)(Cl)(2)]-treated kidney proximal tubule epithelial cell (LLC-PK) preparation. Synthesized...
3.
Nagothu K, Bhatt R, Kaushal G, Portilla D
Kidney Int
. 2005 Dec;
68(6):2680-93.
PMID: 16316343
Background: In previous studies we have shown that cisplatin inhibits peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activity and consequently fatty acid oxidation, and these events precede proximal tubule cell death. In addition...
4.
Nagothu K, Rishi A, Jaszewski R, Kucuk O, Majumdar A
Am J Physiol Gastrointest Liver Physiol
. 2004 Apr;
287(3):G541-6.
PMID: 15075253
Although accumulating evidence suggests a chemopreventive role for folic acid (FA) in colorectal carcinogenesis, the underlying mechanisms are largely unknown. Previously, we reported that supplemental FA inhibits the expression and...
5.
Nagothu K, Jaszewski R, Moragoda L, Rishi A, Finkenauer R, Tobi M, et al.
Cancer Detect Prev
. 2003 Aug;
27(4):297-304.
PMID: 12893078
Loss of heterozygosity (LOH) and/or inactivation of tumor suppressor genes are implicated in the initiation and progression of many malignancies, including colorectal cancer. Although accumulating evidence suggests a chemopreventive role...
6.
Majumdar A, Du J, Hatfield J, Levi E, Adsay V, Schmelz E, et al.
Dig Dis Sci
. 2003 May;
48(5):856-64.
PMID: 12772780
Aging and gastrointestinal malignancies, including that of the stomach are associated with increased activation of EGF-receptor (EGFR). Although the intracellular events that regulate this process are poorly understood, we hypothesize...
7.
Marciniak D, Moragoda L, Mohammad R, Yu Y, Nagothu K, Aboukameel A, et al.
Gastroenterology
. 2003 May;
124(5):1337-47.
PMID: 12730874
Background & Aims: Epidermal growth factor receptor is frequently implicated in epithelial cancers and is, therefore, being considered as a potential target for therapy. Recently, we reported the isolation and...